Michael Silverberg to HIV-1
This is a "connection" page, showing publications Michael Silverberg has written about HIV-1.
Connection Strength
2.102
-
Clinical implications of the nelfinavir-proton pump inhibitor drug interaction in patients with human immunodeficiency virus. Pharmacotherapy. 2011 Mar; 31(3):253-61.
Score: 0.372
-
Effectiveness of highly-active antiretroviral therapy by race/ethnicity. AIDS. 2006 Jul 13; 20(11):1531-8.
Score: 0.270
-
Fraction of cases of acquired immunodeficiency syndrome prevented by the interactions of identified restriction gene variants. Am J Epidemiol. 2004 Feb 01; 159(3):232-41.
Score: 0.228
-
Timing and completeness of routine testing for antibodies to human immunodeficiency virus type 1 among active duty members of the U.S. Armed Forces. Mil Med. 2003 Feb; 168(2):160-4.
Score: 0.213
-
Prevalence of Drug-Resistant Minority Variants in Untreated HIV-1-Infected Individuals With and Those Without Transmitted Drug Resistance Detected by Sanger Sequencing. J Infect Dis. 2017 08 01; 216(3):387-391.
Score: 0.145
-
Response to Therapy in Antiretroviral Therapy-Naive Patients With Isolated Nonnucleoside Reverse Transcriptase Inhibitor-Associated Transmitted Drug Resistance. J Acquir Immune Defic Syndr. 2016 06 01; 72(2):171-6.
Score: 0.134
-
Exposure to antiretroviral therapy and risk of cancer in HIV-infected persons. AIDS. 2012 Nov 13; 26(17):2223-31.
Score: 0.105
-
The effect of HIV infection, immunodeficiency, and antiretroviral therapy on the risk of hepatic dysfunction. J Acquir Immune Defic Syndr. 2012 Jul 01; 60(3):321-7.
Score: 0.102
-
Missing data on the estimation of the prevalence of accumulated human immunodeficiency virus drug resistance in patients treated with antiretroviral drugs in north america. Am J Epidemiol. 2011 Sep 15; 174(6):727-35.
Score: 0.096
-
Virologic and immunologic response to HAART, by age and regimen class. AIDS. 2010 Oct 23; 24(16):2469-79.
Score: 0.091
-
Efficacy and safety of ritonavir-boosted and unboosted atazanavir among antiretroviral-naïve patients. HIV Clin Trials. 2008 Nov-Dec; 9(6):367-74.
Score: 0.079
-
CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection. AIDS. 2008 Apr 23; 22(7):841-8.
Score: 0.076
-
Discontinuation of potent antiretroviral therapy: predictive value of and impact on CD4 cell counts and HIV RNA levels. AIDS. 2001 Nov 09; 15(16):2101-8.
Score: 0.049
-
Risk of End-Stage Renal Disease in HIV-Positive Potential Live Kidney Donors. Am J Transplant. 2017 Jul; 17(7):1823-1832.
Score: 0.036
-
Laboratory Measures as Proxies for Primary Care Encounters: Implications for Quantifying Clinical Retention Among HIV-Infected Adults in North America. Am J Epidemiol. 2015 Dec 01; 182(11):952-60.
Score: 0.032
-
Rising Obesity Prevalence and Weight Gain Among Adults Starting Antiretroviral Therapy in the United States and Canada. AIDS Res Hum Retroviruses. 2016 Jan; 32(1):50-8.
Score: 0.032
-
Risk factors for tuberculosis after highly active antiretroviral therapy initiation in the United States and Canada: implications for tuberculosis screening. J Infect Dis. 2011 Sep 15; 204(6):893-901.
Score: 0.024
-
Effects of depression and selective serotonin reuptake inhibitor use on adherence to highly active antiretroviral therapy and on clinical outcomes in HIV-infected patients. J Acquir Immune Defic Syndr. 2008 Mar 01; 47(3):384-90.
Score: 0.019